The North America human papillomavirus (HPV) vaccine market is expected to grow from US$ 2,247.18 million in 2022 to US$ 2,964.96 million by 2028; it is estimated to grow at a CAGR of 4.7% from 2022 to 2028.
The increase in programs for HPV awareness is one of the effective strategies to increase vaccination uptake and eliminate HPV-associated cancers. Dana-Farber Cancer Institute, Boston, US, has initiated the HPV and Related Cancers Outreach Program, which aims to reduce the HPV-related cancer burden in the community through education and vaccination. The outreach program has been developed to address common barriers to vaccination. Through workshops with the City of Boston and the Boston Public Health Commission, youth-serving organizations, Boston Public Schools, Area Health Education Centers organizations, and faith-based and other community-based organizations, people in Boston have been educated about it. Therefore, the growing number of awareness programs is likely to fuel the market growth in the next few years.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America human papillomavirus (HPV) vaccine market . The North America human papillomavirus (HPV) vaccine market is expected to grow at a good CAGR during the forecast period.
North America Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
North America Human Papillomavirus (HPV) Vaccine Market Segmentation
The North America human papillomavirus (HPV) vaccine market is segmented based on type, dosage, age, application, end user, and country. Based on type, the North America human papillomavirus (HPV) vaccine market is segmented into 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine. The quadrivalent HPV vaccine segment would dominate the market in 2022. In terms of dosage, the North America human papillomavirus (HPV) vaccine market is bifurcated into 2 dose and 3 dose. The 2 dose segment would dominate the market in 2022. Based on age, the North America human papillomavirus (HPV) vaccine market is bifurcated into 9 to 14 years and 15 to 45 years. The 9 to 14 years segment would dominate the market in 2022. In terms of application, the North America human papillomavirus (HPV) vaccine market is bifurcated into HPV-attributable cancer and genital warts. The HPV-attributable cancer segment would dominate the market in 2022. Based on end user, the North America human papillomavirus (HPV) vaccine market is segmented into doctors office, community health clinics, school-based health centers, health departments, hospitals, and others. The hospitals segment would dominate the market in 2022. Based on country, the North America human papillomavirus (HPV) vaccine market has been categorized into the US, Canada, and Mexico. The US would dominate the market in 2022.
ChengDu Institute of Biological Products Co., Ltd.; GlaxoSmithKline plc.; Inovio Pharmaceuticals; Merck & Co., Inc.; R-Pharm; Sanofi; Serum Institute of India Pvt. Ltd; Vaccitech; and Walvax Biotechnology Co., Ltd. are among the leading companies in the North America human papillomavirus (HPV) vaccine market.
At 4.7% CAGR, the North America Human Papillomavirus (HPV) Vaccine Market is speculated to be worth US$ 2,964.96 million by 2028, says The Insight Partners
According to The Insight Partners’ research, the North America human papillomavirus (HPV) vaccine market was valued at US$ 2,247.18 million in 2022 and is expected to reach US$ 2,964.96 million by 2028, registering an annual growth rate of 4.7% from 2022 to 2028. Increase in prevalence of HPV associated diseases and growing number of hpv awareness programs are the critical factors attributed to the market expansion.
Human papillomavirus (HPV) is a common sexually transmitted infection and can cause cervical, oropharyngeal cancer, and cancer of the vagina, vulva, penis, or anus. It also causes various diseases, such as anogenital warts and recurrent respiratory papillomatosis. HPVs have also been detected in lichen sclerosus, skin tags, seborrheic keratoses, epidermal cysts, actinic keratoses, and psoriatic plaques. A significant burden of HPV-associated diseases is likely to drive the market's growth. In women, cervical cancer is the fourth most common cancer. Additionally, the American Society of Clinical Oncology (ASCO) estimated that around 14,100 cases of invasive cervical cancer would be registered in the US alone. Further, as per the report, 'Cervical cancer burden in EU-27,' in 2020, there were 30,447 new cases and 13,437 deaths due to cervical cancer in women. Further, as per the Centers for Disease Control and Prevention (CDC), in 2018, there were around 43 million HPV infections in the US. The CDC also estimated that about 19,400 women and 12,100 men annually suffer from cancers caused by HPV. Further, as per the National Foundation for Infectious Diseases (NFID), there are around 14 million new HPV infection cases in the US every year. Such a high incidence rate of HPV-associated infections is favoring the market growth.
On the contrary, high cost of HPV vaccines hurdles the growth of North America human papillomavirus (HPV) vaccine market.
Based on type, the North America human papillomavirus (HPV) vaccine market is segmented into 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine. The quadrivalent HPV vaccine segment held 61.0% market share in 2022, amassing US$ 1,371.60 million. It is projected to garner US$ 1,805.85 million by 2028 to expand at 4.7% CAGR during 2022–2028.
Based on dosage, the North America human papillomavirus (HPV) vaccine market is bifurcated into 2 dose and 3 dose. The 2 dose segment held 59.6% market share in 2022, amassing US$ 1,339.83 million. It is projected to garner US$ 1,739.07 million by 2028 to expand at 4.4% CAGR during 2022–2028.
Based on age, the North America human papillomavirus (HPV) vaccine market is bifurcated into 9 to 14 years and 15 to 45 years. The 9 to 14 years segment held 71.2% market share in 2022, amassing US$ 1,600.18 million. It is projected to garner US$ 2,134.50 million by 2028 to expand at 4.9% CAGR during 2022–2028.
Based on application, the North America human papillomavirus (HPV) vaccine market is bifurcated into HPV-attributable cancer and genital warts. The HPV-attributable cancer segment held 80.9% market share in 2022, amassing US$ 1,818.31 million. It is projected to garner US$ 2,429.30 million by 2028 to expand at 4.9% CAGR during 2022–2028.
Based on end user, the North America human papillomavirus (HPV) vaccine market is segmented into doctors office, community health clinics, school-based health centers, health departments, hospitals, and others. The hospitals segment held 42.8% market share in 2022, amassing US$ 962.16 million. It is projected to garner US$ 1,253.27 million by 2028 to expand at 4.5% CAGR during 2022–2028.
Based on country, the North America human papillomavirus (HPV) vaccine market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 87.6% market share in 2022. It was assessed at US$ 1,969.43 million in 2022 and is likely to hit US$ 2,577.14 million by 2028, exhibiting a CAGR of 4.6% during the forecast period.
Key players dominating the North America human papillomavirus (HPV) vaccine market are ChengDu Institute of Biological Products Co., Ltd.; GlaxoSmithKline plc.; Inovio Pharmaceuticals; Merck & Co., Inc.; R-Pharm; Sanofi; Serum Institute of India Pvt. Ltd; Vaccitech; and Walvax Biotechnology Co., Ltd. among others.
• In Nov 2021, Merck announced the successful completion of the acquisition of Acceleron Pharma Inc.
• In Feb 2021, QIAGEN and INOVIO Pharmaceuticals announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO's therapies.
TABLE OF CONTENTS
1. Introduction
1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Human Papillomavirus (HPV) Vaccines Market – By Type
1.3.2 North America Human Papillomavirus (HPV) Vaccines Market – By Dosage
1.3.3 North America Human Papillomavirus (HPV) Vaccines Market – By Age
1.3.4 North America Human Papillomavirus (HPV) Vaccines Market – By Application
1.3.5 North America Human Papillomavirus (HPV) Vaccines Market – By Distribution Channel
1.3.6 North America Human Papillomavirus (HPV) Vaccines Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Human Papillomavirus (HPV) Vaccine Market – Market Landscape
4.1 Overview
4.2 North America PEST Analysis
4.3 Experts Opinion
5. North America Human Papillomavirus (HPV) Vaccine Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increase in Prevalence of HPV Associated Diseases
5.1.2 Initiatives Taken by Health Organizations
5.2 Market Restraints
5.2.1 High Cost of HPV Vaccines
5.3 Market Opportunities
5.3.1 Growing Number of HPV Awareness Programs
5.4 Future Trends
5.4.1 Advancements in HPV Diagnostics Tests
5.5 Impact Analysis
6. Human Papillomavirus (HPV) Vaccine Market– North America Analysis
6.1 North America Human Papillomavirus (HPV) Vaccine Market Revenue Forecast and Analysis
7. North America Human Papillomavirus (HPV) Vaccine Market Analysis – By Type
7.1 Overview
7.2 By Type: Market Revenue and Forecast Analysis (US$ Million)
7.3 9-valent HPV vaccine
7.3.1 Overview
7.3.2 9-valent HPV vaccine Market Revenue and Forecast to 2028 (US$ Million)
7.4 Quadrivalent HPV vaccine
7.4.1 Overview
7.4.2 Quadrivalent HPV vaccine Market Revenue and Forecast to 2028 (US$ Million)
7.5 Bivalent HPV Vaccine
7.5.1 Overview
7.5.2 Bivalent HPV Vaccine Market Revenue and Forecast to 2028 (US$ Million)
8. North America Human Papillomavirus (HPV) Vaccine Market Analysis - By Dosage
8.1 North America Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Dosage (2022 and 2028)
8.2 2 Dose
8.2.1 Overview
8.2.2 2 Dose: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
8.3 3 Dose
8.3.1 Overview
8.3.2 3 Dose: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
9. North America Human Papillomavirus (HPV) Vaccine Market Analysis - By Age
9.1 North America Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Age (2022 and 2028)
9.2 9 to 14 Years
9.2.1 Overview
9.2.2 9 to 14 Years: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
9.3 to 45 Years
9.3.1 Overview
9.3.2 to 45 Years: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
10. North America Human Papillomavirus (HPV) Vaccine Market Analysis - By Application
10.1 North America Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Application (2022 and 2028)
10.2 HPV-attributable Cancer
10.2.1 Overview
10.2.2 HPV-attributable Cancer: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
10.3 Genital Warts
10.3.1 Overview
10.3.2 Genital Warts: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
11. North America Human Papillomavirus (HPV) Vaccine Market Analysis – By End User
11.1 Overview
11.2 North America Human Papillomavirus (HPV) Vaccine Market Revenue Share, by End User (2022 and 2028)
11.3 Doctor Office
11.3.1 Overview
11.3.2 Doctor Office Market Revenue and Forecast to 2028 (US$ Million)
11.4 Community Health Clinics
11.4.1 Overview
11.4.2 Community Health Clinics Market Revenue and Forecast to 2028 (US$ Million)
11.5 School-based Health Centers
11.5.1 Overview
11.5.2 School-based Health Centers Market Revenue and Forecast to 2028 (US$ Million)
11.6 Health Departments
11.6.1 Overview
11.6.2 Health Departments Market Revenue and Forecast to 2028 (US$ Million)
11.7 Hospitals
11.7.1 Overview
11.7.2 Hospitals Market Revenue and Forecast to 2028 (US$ Million)
11.8 Others
11.8.1 Overview
11.8.2 Others Market Revenue and Forecast to 2028 (US$ Million)
12. North America Human Papillomavirus (HPV) Vaccine Market - Country Analysis
12.1 North America: Human Papillomavirus (HPV) Vaccine Market
12.1.1 Overview
12.1.2 North America: Human Papillomavirus (HPV) Vaccine Market, by Country, 2022 & 2028 (%)
12.1.2.1 US: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.1.2.1.1 Overview
12.1.2.1.2 US: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.1.2.1.3 US: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)
12.1.2.1.4 US: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)
12.1.2.1.5 US: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)
12.1.2.1.6 US: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)
12.1.2.1.7 US: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)
12.1.2.2 Canada: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.1.2.2.1 Overview
12.1.2.2.2 Canada: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.1.2.2.3 Canada: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)
12.1.2.2.4 Canada: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)
12.1.2.2.5 Canada: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)
12.1.2.2.6 Canada: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)
12.1.2.2.7 Canada: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)
12.1.2.3 Mexico: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.1.2.3.1 Overview
12.1.2.3.2 Mexico: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
12.1.2.3.3 Mexico: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)
12.1.2.3.4 Mexico: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)
12.1.2.3.5 Mexico: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)
12.1.2.3.6 Mexico: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)
12.1.2.3.7 Mexico: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)
13. Industry Landscape
13.1 Overview
13.2 Inorganic Growth Strategies
13.2.1 Overview
13.3 Organic Growth Strategies
13.3.1 Overview
14. Company Profiles
14.1 Merck & Co., Inc.
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 GlaxoSmithKline plc.
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Serum Institute of India Pvt. Ltd
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Walvax Biotechnology Co., Ltd.
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Inovio Pharmaceuticals
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Vaccitech
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 ChengDu Institute of Biological Products Co., Ltd.
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Sanofi
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 R-Pharm
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
15. Appendix
15.1 About The Insight Partners
15.2 Glossary of Terms
LIST OF TABLES.
Table 1. North America Human Papillomavirus (HPV) Vaccine Market, Revenue and Forecast, 2019–2028 (US$ Mn)
Table 2. US Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 3. US Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
Table 4. US Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
Table 5. US Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 6. US Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 7. Canada: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 8. Canada Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
Table 9. Canada Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
Table 10. Canada Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 11. Canada Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 12. Mexico: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 13. Mexico Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)
Table 14. Mexico Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)
Table 15. Mexico Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 16. Mexico Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 17. Recent Inorganic Growth Strategies
Table 18. Recent Organic Growth Strategies
Table 19. Glossary of Terms
LIST OF FIGURES.
Figure 1. North America Human Papillomavirus (HPV) Vaccines Market Segmentation
Figure 2. North America Human Papillomavirus (HPV) Vaccines Market, By Country
Figure 3. North America Human Papillomavirus (HPV) Vaccine Market Overview
Figure 4. North America Human Papillomavirus (HPV) Vaccines Market, By Type
Figure 5. North America Human Papillomavirus (HPV) Vaccines Market, By Country
Figure 6. North America: PEST Analysis
Figure 7. Experts Opinion
Figure 8. North America Human Papillomavirus (HPV) Vaccines Market Impact Analysis of Driver and Restraints
Figure 9. North America Human Papillomavirus (HPV) Vaccine Market– Revenue Forecast and Analysis
Figure 10. By Type: Market Analysis and Forecast 2022 and 2028 (%)
Figure 11. North America 9-valent HPV vaccine Market Revenue and Forecast to 2028 (US$ Million)
Figure 12. North America Quadrivalent HPV vaccine Market Revenue and Forecast to 2028 (US$ Million)
Figure 13. North America Bivalent HPV Vaccine Market Revenue and Forecast to 2028 (US$ Million)
Figure 14. North America Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Dosage (2022 and 2028)
Figure 15. North America 2 Dose: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. North America 3 Dose: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. North America Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Age (2022 and 2028)
Figure 18. North America 9 to 14 Years: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. North America 15 to 45 Years: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. North America Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Application (2022 and 2028)
Figure 21. North America HPV-attributable Cancer: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. North America Genital Warts: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. North America Human Papillomavirus (HPV) Vaccine Market Revenue Share, by End User (2022 and 2028)
Figure 24. North America Doctor Office Market Revenue and Forecast to 2028 (US$ Million)
Figure 25. North America Community Health Clinics Market Revenue and Forecast to 2028 (US$ Million)
Figure 26. North America School-based Health Centers Market Revenue and Forecast to 2028 (US$ Million)
Figure 27. North America Health Departments Market Revenue and Forecast to 2028 (US$ Million)
Figure 28. North America Hospitals Market Revenue and Forecast to 2028 (US$ Million)
Figure 29. North America Others Market Revenue and Forecast to 2028 (US$ Million)
Figure 30. North America: Human Papillomavirus (HPV) Vaccine Market, by Key Country – Revenue (2022) (US$ Million)
Figure 31. North America: Human Papillomavirus (HPV) Vaccine Market, by Country, 2022 & 2028 (%)
Figure 32. US: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33. Canada: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. Mexico: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
